Organizational Governance |
|
- 【Integrated Report 2023】
- Message from the President(P8)
- Sumitomo Pharma Group’s Material Issues(P22)
- Sumitomo Pharma’s Value Creation Process(P23)
- Vision and Position We Aspire to Establish by 2033(P24)
- Corporate Governance(P38)
|
Human Rights |
1. Due diligence |
|
2. Human rights risk situations |
3. Avoidance of complicity |
4. Resolving grievances |
|
5. Discrimination and vulnerable groups |
|
6. Civil and political rights |
7. Economic, social and cultural rights |
8. Fundamental principles and rights at work |
|
Labour Practices |
1. Employment and employment relationships |
|
2. Conditions of work and social protection |
3. Social dialogue |
|
4. Health and safety at work |
|
5. Human development and training in the workplace |
|
The Environment Management |
1. Prevention of pollution |
|
2. Sustainable resource use |
3. Climate change mitigation and adaptation |
4. Protection of the environment, biodiversity and restoration of natural habitats |
|
Fair Operating Practices |
1. Anti-corruption |
|
2. Responsible political involvement |
|
3. Fair competition |
|
4. Promoting social responsibility in the value chain |
|
5. Respect for property rights |
|
Consumer Issues |
1. Fair marketing, factual and unbiased information and fair contractual practice |
|
2. Protecting consumers' health and safety |
|
3. Sustainable consumption |
|
4. Consumer service, support, and complaint and dispute resolution |
|
5. Consumer data protection and privacy |
|
6. Access to essential services |
|
7. Education and awareness |
|
Community Involvement and Development |
1. Community involvement |
|
2. Education and culture |
|
3. Employment creation and skills development |
|
4. Technology development and access |
|
5. Wealth and income creation |
|
6. Health |
|
7. Social investment |